Combination therapy with selective SMARCA2 (BRM) degraders for treatment of SMARCA4 (BRG1)-deficient cancers

Michael Hulse, Margot Elkins, Jessica Burtell, KomaliVykuntam, Philip Pitis, Liang Lu, Kris Vaddi, Andrew Combs, Koichi Ito, Peggy Scherle